

Elizabeth Jungman

Experience

THE PEW CHARITABLE TRUSTS

Washington, DC

Director, Drug Safety and Innovation (January 2014-Present)

Responsible for overseeing Pew teams focused on drug safety, prescription drug abuse, and antibiotics and innovation.

- As part of the Drug Safety team, work to protect consumers from substandard, counterfeit, and adulterated medicines through legislative and regulatory reforms designed to: reduce the risks of an increasingly globalized and outsourced drug manufacturing system, strengthen quality standards and oversight for drug manufacturing and drug compounding, create a national tracking system to secure drug distribution, and assess the root causes of drug shortages.
- With the Antibiotics and Innovation team: generate and advocate policy to spur the development of new antibiotics for serious or life-threatening infections by addressing the scientific, economic, and regulatory challenges that hinder progress in antibiotic development.
- Launch a new Prescription Drug Abuse initiative to utilize federal and state policy levers to reduce the serious health and economic consequences of prescription drug abuse.
- For all teams: maintain and develop relationships with outside stakeholder organizations, including major national consumer and public health advocacy groups.
- Maintain and develop a critical understanding of academic research related to team work areas.

U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR & PENSIONS

Washington, DC

Senior Health Policy Advisor (March 2011-December 2013)

Lead staff member on Food and Drug Administration (FDA) issues for the Senate Committee with authorizing jurisdiction over FDA.

- Advised Chairman Tom Harkin and Committee leadership and staff on legislative and oversight matters related to the FDA.
- Played a key role in drafting and negotiating significant legislation on drug quality, drug safety, drug development, and related regulatory modernization:
 - The FDA Safety and Innovation Act of 2012, which included policy related to pediatric research incentives, medical device approval, the safety of drug imports, expedited drug approvals, and other matters;
 - The FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, which included process changes to streamline the regulatory pathway for medical countermeasures; and
 - The Drug Quality and Security Act of 2013, which clarified the regulation of traditional compounders, created a new federal regulatory category for facilities that compound drugs outside of the traditional pharmacy setting, established a national tracking system to secure drug distribution, and raised licensure standards for pharmaceutical wholesale distributors.
- Engaged with stakeholder groups during policy development, including major national organizations in the consumer and public health advocacy communities. Worked with these stakeholders to understand recommendations and refine policy proposals as appropriate to protect the public health.

COVINGTON & BURLING LLP

Washington, DC

Associate (October 2005-March 2011)

Provided regulatory advice as a member of the firm's Food & Drug and Health Care practice groups. Developed deep technical expertise on a broad range of pharmaceutical law and regulatory topics.

- Advised clients on human pharmaceutical matters such as pharmaceutical advertising and promotion, Hatch-Waxman and pediatric exclusivity, bioequivalence, drug naming, and compliance programs.
- Counseled clients on health care issues including fraud and abuse risk analysis, price reporting, pharmaceutical and clinical trials reimbursement, drug coverage under the Medicare prescription drug program, and compliance with HIPAA and other medical privacy laws.
- Provided regulatory support for litigation pleadings and corporate transactions and filings.
- Pro-bono projects related to public benefits and end-of-life planning.

UNITED STATES COURT OF APPEALS, NINTH CIRCUIT

Seattle, WA

Law Clerk for the Hon. Richard C. Tallman (August 2004–August 2005)

Researched and drafted bench memoranda, and proposed opinions related to various areas of law.

UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA

Los Angeles, CA

Law Clerk for the Hon. Mariana R. Pfaelzer (August 2003–August 2004)

Researched and drafted bench memoranda, memorandum opinions, and orders primarily related to biotechnology patent and antitrust actions.

Education

GEORGETOWN UNIVERSITY LAW CENTER

J.D., *cum laude*, May 2003

JOHNS HOPKINS SCHOOL OF PUBLIC HEALTH

M.P.H., concentration in Health Policy & Management, May 2003

HARVARD COLLEGE

A.B. in Biology, *cum laude*, June 1998